Brief: Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
06/02/2025 13:34
Feb 6 (Reuters) - Biocon Ltd BION.NS :
* EQUILLIUM ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY
EVALUATING
ITOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE
COLITIS
* EQUILLIUM INC - ITOLIZUMAB GENERALLY WELL TOLERATED IN
PHASE 2
STUDY
* EQUILLIUM INC - ITOLIZUMAB ACHIEVES 16.7% ENDOSCOPIC
REMISSION
IN PHASE 2 STUDY
Source text: ID:nBwbcr7K5a
Further company coverage: BION.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations